Use your antibodies-online credentials, if available.
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. 再加上，我们可以发PCSK9 试剂盒 (72) 和 PCSK9 蛋白 (61)和数多这个蛋白质的别的产品。
Showing 10 out of 154 products:
Human Polyclonal PCSK9 Primary Antibody for ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005
Show all 10 references for ABIN268772
Human Polyclonal PCSK9 Primary Antibody for IHC (p), WB - ABIN374535
Lambert, Ancellin, Charlton, Comas, Pilot, Keech, Patel, Sullivan, Cohn, Rye, Barter: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. in Clinical chemistry 2008
Show all 3 references for ABIN374535
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. in The Journal of biological chemistry 2009
Show all 3 references for ABIN453778
Human Polyclonal PCSK9 Primary Antibody for IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005
Show all 2 references for ABIN185371
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN391505
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. in Journal of human genetics 2004
Show all 2 references for ABIN391505
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN652320
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... in Nature genetics 2003
Show all 2 references for ABIN652320
Human Polyclonal PCSK9 Primary Antibody for IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008
LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of PCSK9 rs11206510 (n = 799) but not in non-C-allele carriers (n = 3188).
the zymogen form of PCSK9 adopts a structure that is distinct from the processed form and is unable to bind a mimetic peptide based on the EGF (显示 EGF 抗体)-A domain of the LDLr (显示 LDLR 抗体).
CRP (显示 CRP 抗体) increased PCSK9 expression by activating p38MAPK (显示 MAPK14 抗体)-HNF1alpha (显示 HNF1A 抗体) pathway, with a certain downstream impairment in LDL metabolism in HepG2 cells.
PCSK9 C-terminal domain (CTD) was found to be essential to induce LDLR (显示 LDLR 抗体) degradation both upon its overexpression in cells or via the extracellular pathway.
Results show that circulating PCSK9 concentration increases with the severity of hepatic fat accumulation in patients at risk of nonalcoholic fatty liver disease.
PCSK9 inhibition with alirocumab on top of statin treatment has the potential to lower LDL cholesterol in some autosomal recessive hypercholesterolemia patients.
CRISPR-Cas9 therapy targeting the human PCSK9 gene in chimeric liver-humanized mice bearing human hepatocytes.
PCSK9 regulates monocyte CCR2 expression and chemotaxis.
PCSK9 is down-regulated in patients with rheumatoid arthritis.
Carriers of the PCSK9 R46L genetic variant have lower very low-density lipoprotein and low-density lipoprotein particle concentrations, lower lipoprotein(a) levels, and lower secretory phospholipase A2 (显示 YWHAZ 抗体) and lipoprotein-associated phospholipase A2 activity, reducing cardiovascular risk.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (显示 APOE 抗体)(-/-) mice.
Adeno (显示 ADORA2A 抗体)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (显示 CA2 抗体)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (显示 LDLR 抗体) degradation and promoting LDLR (显示 LDLR 抗体)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (显示 LDLR 抗体) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (显示 APOE 抗体)- and LDLR (显示 LDLR 抗体)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
binding of PCSK9 to GRP94 (显示 HSP90B1 抗体) protects LDLR (显示 LDLR 抗体) from degradation likely by preventing early binding of PCSK9 to LDLR (显示 LDLR 抗体)
The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR (显示 LDLR 抗体) and VLDLR (显示 VLDLR 抗体), which is determined by estradiol levels.
that ox-LDL receptor-1 (显示 OLR1 抗体) and PCSK9 positively influence each other's expression, especially during an inflammatory reaction
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9